Background: It has been found that the expression of fatty acid-binding protein 2 gene mRNA is under dietary control. The polymorphism Ala54Thr of this protein was associated with high insulin resistance. Objective: The aim of our study was to investigate the influence of Thr54 polymorphism on metabolic response, weight loss and serum adipokine levels secondary to high-protein/low-carbohydrate vs. standard hypocaloric diets during 9 months. Design: A population of 193 obese subjects was analyzed in a randomized trial. A nutritional evaluation was performed at the beginning and at the end of a 9-month period in which subjects received 1 of 2 diets (diet HP: high-protein/low-carbohydrate vs. diet S: standard diet). Results: With both diets and in both genotype groups, body mass index, weight, fat mass, waist circumference, systolic blood pressure and leptin levels decreased. With both diets and only in wild genotype (diet HP vs. diet S), glucose (-6.2 ± 2.1 vs. -4.9 ± 2.0 mg/dl; p < 0.05), insulin levels (-5.0 ± 3.9 vs. -2.0 ± 2.1 UI/l; p < 0.05), homeostasis model assessment for insulin resistance (HOMA-R) (-1.1 ± 0.9 vs. -0.7 ± 1.0 units; p < 0.05) decreased. The improvement in these parameters was higher with diet HP than HS. With both diets and only in the wild genotype, total cholesterol and LDL-total cholesterol levels decreased. Conclusion: Carriers of Thr54 allele have a different metabolic response after weight loss than wild type non-A carriers obese, with a lack of decrease of LDL-cholesterol, glucose, insulin levels and HOMA-R.

1.
Hu T, Mills KT, Yao L, et al: Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 2012;176(suppl 7):S44-S54.
2.
Castañeda-González LM, Bacardí Gascón M, Jiménez Cruz A: Effects of low carbohydrate diets on weight and glycemic control among type 2 diabetes individuals: a systemic review of RCT greater than 12 weeks. Nutr Hosp 2011;26:1270-1276.
3.
Nordmann AJ, Nordmann A, Briel M, et al: Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:285-293.
4.
Bueno NB, de Melo IS, de Oliveira SL, et al: Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr 2013;110:1178-1187.
5.
Nordmann AJ, Suter-Zimmermann K, Bucher HC, et al: Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. Am J Med 2011;124:841-851.e2.
6.
de Luis DA, Sagrado MG, Aller R, Izaola O, Conde R: Influence of Ala54Thr polymorphism of fatty acid-binding protein 2 on obesity and cardiovascular risk factors. Horm Metab Res 2007;39:830-834.
7.
Pérez-Sanz TM, de Luis DA: Fatty acid binding proteins and cardiovascular risk. Curr Cardiovasc Risk Rep 2013;7:17-24.
8.
Baier LJ, Sacchettini JC, Knowler WC: An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995;95:1281-1287.
9.
de Luis DA, Aller R, Izaola O, Conde R, Gonzalez M: Modulation of the response to a lyfestile modification in obese patients by Ala54Thr polymorfism of the fatty acid-binding protein 2 gene. Ann Nutr Metab 2006;50:354-360.
10.
Weiss EP, Brandauer J, Kulaputana O, Ghiu IA, Wohn CR, Phares DA, Shuldiner AR, Hagberg JM: FABP2 Ala54Thr genotype is associated with glucoregulatory function and lipid oxidation after a high-fat meal in sedentary nondiabetic men and women. Am J Clin Nutr 2007;85:102-108.
11.
de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R: Fatty acid-binding protein 2 Ala54Thr genotype is associated with insulin resistance and leptin levels changes after a high monounsaturated fat diet in obese non-diabetic patients. J Endocrinol Invest 2013;36:402-406.
12.
de Luis D, Aller R, Izaola O, Sagrado MG, de la Fuente B, Conde R, Primo D: Effect of fatty acid-binding protein 2 Ala54Thr genotype on weight loss and cardiovascular risk factors after a high-polyunsaturated fat diet in obese patients. J Investig Med 2012;60:1194-1198.
13.
Matsuzawa Y: Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep 2005;7:58-62.
14.
Okazaki T, Himeno E, Nanri H, Ogata H, Ikeda M: Effects of mild aerobic exercise and a mild hypocaloric diet on plasma leptin in sedentary women. Clin Exp Pharmacol Physiol 1999;26:415-420.
15.
Xenachis C, Samojlik E, Raghuwanshi MP, Kirschner MA: Leptin, insulin and TNF-alpha in weight loss. J Endocrinol Invest 2001;24:865-870.
16.
Mataix J, Mañas M, et al: Tablas de Composición de Alimentos Españoles, ed 4. University of Granada, 2003.
17.
Duart Duart MJ, Arroyo CO, Moreno Frígols JL: Validation of a kinetic model for the reactions in RIA. Clin Chem Lab Med 2002;40:1161-1167.
18.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
19.
Lehmann HP, Block D, Markert-Hahn C, Zolg JW: New concepts in systemic autoimmunity testing. Scand J Clin Lab Invest Suppl 2001;235:84-90.
20.
Lukaski HC, Johnson PE, et al: Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985;41:810-817.
21.
Dworatzek PD, Hegele RA, Wolever TM: Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. AM J Clin Nutr 2004;79:1110-1117.
22.
Marín C, Pérez-Jiménez F, Gómez P, Delgado J, Paniagua JA, Lozano A, Cortés B, Jiménez-Gómez Y, Gómez MJ, López-Miranda J: The Ala54Thr polymorphism of the fatty acid-binding protein 2 gene is associated with a change in insulin sensitivity after a change in the type of dietary fat. Am J Clin Nutr 2005;82:196-200.
23.
Martinez-Lopez E, Garcia-Garcia MR, Gonzalez-Avalos JM, Maldonado-Gonzalez M, Ruiz-Madrigal B, Vizmanos B, Hernandez-Nazara Z, Roman S, Panduro A: Effect of Ala54Thr polymorphism of FABP2 on anthropometric and biochemical variables in response to a moderate-fat diet. Nutrition 2013;29:46-51.
24.
McColley SP, Georgopoulos A, Young LR, Kurzer MS, Redmon JB, Raatz SK: A high-fat diet and the threonine-encoding allele (Thr54) polymorphism of fatty acid-binding protein 2 reduce plasma triglyceride-rich lipoproteins. Nutr Res 2011;31:503-508.
25.
Hegele RA, Wolever TM, Story JA, Connelly PW, Jenkins DJ: Intestinal fatty acid-binding protein variation associated with variation in the response of plasma lipoproteins to dietary fibre. Eur J Clin Invest 1997;27:857-862.
26.
Carlsson M, Orho-Melander M, Hedenbro J, Almgren P, Groop LC: The T 54 allele of the intestinal fatty acid-binding protein 2 is associated with a parental history of stroke. J Clin Endocrinol Metab 2000;85:2801-2804.
27.
Georgopoulos A, Aras O, Noutsou M, Tsai MY: Unlike type 2 diabetes, type 1 does not interact with the codon 54 polymorphism of the fatty acid binding protein 2 gene. J Clin Endocrinol Metab 2002;87:3735-3739.
28.
Santos FL, Esteves SS, da Costa Pereira A, et al: Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev 2012;13:1048-1066.
29.
Kodama S, Saito K, Tanaka S, et al: Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:959-965.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.